Braveheart Bio Q2 Net Loss Widens

04:29 PM EDT, 09/08/2026 (MT Newswires) -- Braveheart Bio (BRVE) reported a Q2 net loss late Tuesday of $2.51 per diluted share, widening from the loss of $0.14 a year earlier. The company said its cash and cash equivalents were $122.8 million as of June 30. Including net proceeds from the August initial public offering, cash and cash equivalents would have been $527.3 million on an as-adjusted basis. Braveheart Bio expects its cash and cash equivalents, along with the IPO proceeds, to fund projected operating expenses and capital expenditure requirements into 2029.